SEC Form 4 · accession 0001239594-26-000008
Caris Life Sciences, Inc. · CAI
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Peter M Castleman
Director
Period of report
Aug 14, 2026
Accepted (ET)
Aug 14, 2026 · 5:44 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0002019410
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Aug 14, 2026 | A | 13,192 | $0.00 | A | 29,321 | D | |
| Common Stock | holding | — | — | — | 108,009 | I | By Family Trust | |
| Common StockF2,F3 | holding | — | — | — | 10,546,384 | I | By CLS-PF-SPE, LLC |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Represents an award of restricted stock units which vest in accordance with the applicable grant agreement.
- F2Includes shares received in pro rata distributions exempt pursuant to Rule 16a-9.
- F3CLS-PF-SPE Manager, LLC is the manager of CLS-PF-SPE, LLC. Mr. Castleman is a manager of CLS-PF-SPE Manager, LLC and in such capacity has voting and investment power with respect to the shares held by CLS-PF-SPE, LLC. The Reporting Person disclaims beneficial ownership except to the extent of his pecuniary interest therein.